Communication

The Design and Evaluation of Heparin-Binding Foldamers†

  1. Sungwook Choi1,2,
  2. Dylan J. Clements2,
  3. Vojislava Pophristic Prof. Dr.3,
  4. Ivaylo Ivanov Dr.1,
  5. Satyavani Vemparala Dr.1,
  6. Joel S. Bennett Prof. Dr.4,
  7. Michael L. Klein Prof. Dr.1,
  8. Jeffrey D. Winkler Prof. Dr.1,
  9. William F. DeGrado Prof. Dr.1,2

Article first published online: 11 AUG 2005

DOI: 10.1002/anie.200501279

Issue

Angewandte Chemie International Edition

Angewandte Chemie International Edition

Volume 44, Issue 41, pages 6685–6689, October 21, 2005

Additional Information

How to Cite

Choi, S., Clements, D. J., Pophristic, V., Ivanov, I., Vemparala, S., Bennett, J. S., Klein, M. L., Winkler, J. D. and DeGrado, W. F. (2005), The Design and Evaluation of Heparin-Binding Foldamers. Angewandte Chemie International Edition, 44: 6685–6689. doi: 10.1002/anie.200501279

Author Information

  1. 1

    Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6323, USA, Fax: (+1) 215-573-7229

  2. 2

    Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104-6059, USA

  3. 3

    Department of Chemistry and Biochemistry, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA

  4. 4

    Department of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA 19104, USA

  1. †

    We thank the National Institutes of Health (grant no. 65803), PolyMedix, Inc., and Burroughs Wellcome Fund (fellowship to I.I) for financial support

Publication History

  1. Issue published online: 14 OCT 2005
  2. Article first published online: 11 AUG 2005
  3. Manuscript Received: 12 APR 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (182K)

Keywords:

  • antithrombin;
  • heparin;
  • inhibitors;
  • oligomers;
  • protein interactions

Graphical Abstract

Thumbnail image of graphical abstract

Controlling blood loss: The synthesis of a series of arylamide oligomers 1, which interact with heparin is described. The heparin–small molecule interaction inhibits the heparin's ability to activate antithrombin. These arylamide oligomers are the first example of low-molecular-weight antagonists that inhibit the anticoagulant function of heparin.

View Full Article with Supporting Information (HTML) Get PDF (182K)